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Abstract
Introduction: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss
of dopaminergic neurons as well as the presence of proteinaceous inclusions named Lewy bodies.
α-synuclein (α-syn) is a major constituent of Lewy bodies, and the first disease-causing protein characterized
in PD. Several α-syn-based animal models of PD have been developed to investigate the pathophysiology
of PD, but none of them recapitulate the full picture of the disease. Ageing is the most compelling and
major risk factor for developing PD but its impact on α-syn toxicity remains however unexplored. In this
study, we developed and exploited a recombinant adeno-associated viral (AAV) vector of serotype 9
overexpressing mutated α-syn to elucidate the influence of ageing on the dynamics of PD-related
neurodegeneration associated with α-syn pathology in different mammalian species.
Results: Identical AAV pseudotype 2/9 vectors carrying the DNA for human mutant p.A53T α-syn were injected into the
substantia nigra to induce neurodegeneration and synucleinopathy in mice, rats and monkeys. Rats were used first to
validate the ability of this serotype to replicate α-syn pathology and second to investigate the relationship between the
kinetics of α-syn-induced nigrostriatal degeneration and the progressive onset of motor dysfunctions, strikingly
reminiscent of the impairments observed in PD patients. In mice, AAV2/9-hα-syn injection into the substantia nigra was
associated with accumulation of α-syn and phosphorylated hα-syn, regardless of mouse strain. However, phenotypic
mutants with either accelerated senescence or resistance to senescence did not display differential susceptibility to
hα-syn overexpression. Of note, p-α-syn levels correlated with nigrostriatal degeneration in mice. In monkeys,
hα-syn-induced degeneration of the nigrostriatal pathway was not affected by the age of the animals. Unlike mice, m
onkeys did not exhibit correlations between levels of phosphorylated α-syn and neurodegeneration.
Conclusions: In conclusion, AAV2/9-mediated hα-syn induces robust nigrostriatal neurodegeneration in mice, rats and
monkeys, allowing translational comparisons among species. Ageing, however, neither exacerbated nigrostriatal
neurodegeneration nor α-syn pathology per se. Our unprecedented multi-species investigation thus favours the
multiple-hit hypothesis for PD wherein ageing would merely be an aggravating, additive, factor superimposed upon an
independent disease process.
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Introduction
Parkinson’s disease (PD) is characterized by a profound
loss of dopaminergic neurons from the substantia nigra,
pars compacta (SNpc) associated with the presence of
intraneuronal proteinaceous inclusions, named Lewy
bodies (LB) in cell bodies and Lewy neurites (LN) in
neuritis [1]. Although several genetic loci have been
linked to the development of PD, ageing remains the
most prominent risk factor [2]. Two main hypotheses
have been formulated regarding the influence of ageing:
one proposes that ageing increases dopamine neuron
susceptibility [3] and the other that PD arises from the
combination of several insults over the individual’s life
[4]. Overall, the impact of ageing has been largely over-
looked in preclinical studies of PD.
A major protein component of LB and LN is α-
synuclein (α-syn), a synaptic protein of, as yet, unclear
function [5]. Interestingly, α-syn has a unique import-
ance in the aetiology of PD, as it appears to link familial
and sporadic forms of the disease [6]. Several α-syn
transgenic mice have been developed, expressing human
wild type (WT) or mutated α-syn under different pro-
moters [7]. They failed, however, to reproduce the com-
bination of progressive and specific dopamine cell loss,
protein aggregation and manifestation of parkinsonian-
like symptoms [8]. Subsequently, the development of
lentiviral and recombinant adeno-associated viral vectors
(AAV) has opened up new possibilities regarding disease
modelling. Nevertheless, the literature reports a bewil-
dering variety of vectors, expression cassettes, serotypes,
and titers, that hampers comparison between strains,
species and investigators [8–10].
We, therefore investigated the spatial and temporal dy-
namics of dopamine neuron degeneration, human mu-
tant p.A53T α-syn (hα-syn) expression and the resulting
synucleinopathy using AAV pseudotype 2/9 (AAV2/9) in
different species, namely mouse, rat and marmoset mon-
key. After replicating the progressive degeneration in
rats and characterizing their parkinsonian-like pheno-
type, we questioned whether ageing influences suscepti-
bility of dopamine neurons to neurodegeneration using
senescence-prone and -resistant mouse strains and a
population of marmoset monkeys featuring young and
aged individuals. Our results demonstrate that ageing
does not amplify the neurodegenerative process but sim-
ply adds to the α-syn overexpression supporting the
multi-hit hypothesis.
Materials and methods
Adeno-Associated Viral vector production
Recombinant AAV2/9-p.A53T-human-α-syn (AAV-hα-
syn) vectors were produced by polyethylenimine (PEI)
mediated triple transfection of low passage HEK-293 T
/17 cells (ATCC; cat number CRL-11268). The AAV
expression plasmid pAAV2-CMVie/hSyn-synA53T-
WPRE-pA (provided by Dr V. Baekelandt) was co-
transfected with the adeno helper pAd Delta F6 plasmid
(Penn Vector Core, cat # PL-F-PVADF6) and AAV Rep
Cap pAAV2/9 plasmid (Penn Vector Core, cat # PL-T-
PV008).
AAV vectors were purified as previously described
[11]. Cells are harvested 72 h post transfection, resus-
pended in lysis buffer (150 mM NaCl, 50 mM Tris–HCl
pH 8.5) and lysed by 3 freeze-thaw cycles (37 °C/-80 °C).
The cell lysate is treated with 150units/ml Benzonase
(Sigma, St Louis, MO) for 1 h at 37 °C and the crude
lysate is clarified by centrifugation. Vectors are purified
by iodixanol step gradient centrifugation, and concen-
trated and buffer-exchanged into Lactated Ringer’s so-
lution (Baxter, Deerfield, IL) using vivaspin20 100 kDa
cut off concentrator (Sartorius Stedim, Goettingen,
Germany).
Titrations were performed at the transcriptome
core facility (Neurocentre Magendie, INSERM U862,
Bordeaux, France). The genome-containing particle
(gcp) titer was determined by quantitative real-time
PCR using the Light Cycler 480 SYBR green master
mix (Roche, cat # 04887352001) with primers specific
for the AAV2 ITRs (fwd 5’-GGAACCCCTAGTGATG
GAGTT-3’; rev 5’-CGGCCTCAGTGAGCGA-3’) [12]
on a Light Cycler 480 instrument.
Purity assessment of vector stocks was estimated by
loading 10 μl of vector stock on 10 % SDS acrylamide
gels, total proteins were visualized using the Krypton In-
frared Protein Stain according to the manufacturer’s in-
structions (Life Technologies).
Animals
Experiments were performed in accordance with the
European Union directive of September 22, 2010 (2010/
63/EU) on the protection of animals used for scientific
purposes. The Institutional Animal Care and Use Com-
mittee of Bordeaux (CE50) approved experiments under
the license number 5012099-A (rodents) and 50120102-
A (monkeys). Kinematics experiments were performed
under the guidelines established at EPFL. Local Swiss
Veterinary Offices approved all the procedures. Experi-
ments were performed on Sprague Dawley (53 animals),
Wistar (8 animals) and Lewis rats (10 animals) with ini-
tial weight of approximately 200 g and age of 8 weeks.
Rats were ordered from Janvier Labs or Charles River in
France. Mouse experiments were performed on C57Bl/
6 J (12 animals – ordered from Charles River laborator-
ies), SAMR1 (19 animals) and SAMP8 (21 animals).
Both SAMR1 and SAMP8 were purchased from the re-
search animal facility of the Barcelona Science Park
(Barcelona, Spain).
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Monkey experiments were performed in an Associ-
ation for Assessment and Accreditation of Laboratory
Animal Care accredited facility following acceptance
of study design by the Institute of Lab Animal Sci-
ence (Chinese Academy of Science, Beijing, China)
Institutional Animal Care and Use Committee. Thir-
teen male marmoset monkeys (Callithrix jacchus;
Beijing, People’s Republic of China) were housed in 2
primate cages, allowing visual contacts and interac-
tions with monkeys housed inside the cage. The use
of wood chip or shredded paper litter on the cage
floor is a source of environmental enrichment. Food
and water were available ad libitum and animal care
was supervised daily by veterinarians skilled in the
health care and maintenance of nonhuman primates.
Rodent experiments
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated
mice
Eight- to 10-week-old male C57BL/6 J, SAMP8 and
SAMR1 mice received one intraperitoneal injection of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-HCl
per day (30 mg/kg free base; Sigma) for five consecutive
days. Control mice received saline injections only. Mice
were killed five months after MPTP intoxication. Four
to nine mice were used in each group.
Surgical procedures
All the interventions were performed under full general
anesthesia with isoflurane in oxygen-enriched air (1-
2 %). After surgery, rodents were placed in an incubator
for optimized recovery from anesthesia. Rats were
injected either bilaterally (kinematic recordings,) or uni-
laterally (immunohistochemical investigation and basic
motor behavior (spontaneous locomotor activity and
stepping test)) in the SNpc with the AAV-hα-syn (2 μl -
7.0 ×1012 vg/ml) or the control AAV-GFP (7.0 ×1012
vg/ml – solely for kinematic recordings). Under isoflur-
ane anesthesia, rats were placed in a stereotaxic frame
(Kopf Instruments) and received two bilateral intrani-
gral injections (Anteroposterior: −4.9 and −5.4; Medio-
lateral: ± 2.2 and ± 2; Dorsoventral: −7.8, in mm from
bregma) of either vector, as previously described [13].
Mice were injected unilaterally with the AAV-hα-syn
(120 nl - 7.0 ×1012 vg/ml) in the right SNpc (coordi-
nates from Bregma: AP = −2.9, L = −1.3, DV = −4.5). Vi-
ruses were injected with a glass pipette at 0.4 μl.min−1 and
the pipette was left in place for 4 min after injection to
avoid leakage.
Kinematic Recordings
All procedures used have been detailed previously [14].
Briefly, whole-body kinematics were recorded using the
high-speed motion capture system Vicon (Vicon Motion
Systems, UK), combining 12 infrared cameras (200 Hz).
4 mm reflective markers were attached bilaterally overly-
ing the iliac crest, the greater trochanter (hip), the lateral
condyle (knee), the malleolus (ankle), and the base of
the metatarsal phalageal joint (MTP). 3D position of the
markers was reconstructed offline using Vicon Nexus
software (1.8). The body was modeled as an intercon-
nected chain of rigid segments, and joint angles were
generated accordingly. For subsequent kinematic ana-
lysis, only hindlimb and parameters related to the trunk
were analyzed. Parameters (Additional file 1: Table S1)
describing gait timing, joint kinematics, limb endpoint
trajectory, and trunk stability were computed for each
gait cycle using custom written MATLAB scripts and ac-
cording to methods described previously [14].
Behavioral Tasks
Spontaneous locomotor actimetry Spontaneous loco-
motor activity was evaluated in cages similar to home
cages (35x25x25 cm) flanked with photobeam to allow
computerized counting of horizontal beam breaks
(protocol adapted from [15]. After a 3 h habituation
session, each subsequent recording sessions (i.e., Bsl,
4, 8, 12, 16 weeks) lasted 3 h.
Stepping test Forelimb akinesia was assessed using
stepping [13, 16]. Briefly, animals were gently held
and conducted over a 90 cm distance to allow fore-
hand followed by backhand steps count. Left and
right limb performances were successively evaluated
over 2 daily sessions on 3 consecutive days. The aver-
age number of left/right forehand steps was averaged
over the 6 sessions for each time-point.
Kinematic recordings Rats were handled and trained
during one week prior to surgery in order to accustom
them to the two locomotor tasks. After AAV-hα-syn in-
jection surgery animals were trained 2–3 times per week
and monitored visually to assess whether PD-like symp-
toms had developed. Out of 8 rats initially injected 6 dis-
played observable bradykinesia and were thus included
in the functional analysis. Symptoms emerged at differ-
ent timepoints for the individual rats (8–16 weeks post
injection) and the recordings used for analysis are from
these chronic timepoints. Due to improved functional
performance with training animals were only trained
once a week after symptoms had emerged. Overground
and ladder locomotion were recorded on different days.
One rat was not included in the ladder analysis since
not enough functional steps could be recorded from this
animal in this task. AAV-hα-syn rats were compared to
a set of healthy rats that were extensively trained to per-
form both locomotor tasks.
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Overground locomotion was tested on a 15 cm
wide and 120 cm long, elevated runway. 10–15 steps
per side were analyzed per rat. A total of 89 kine-
matic parameters were computed and included in the
subsequent PC analysis for this task (Additional file 1:
Table S1).
Crossing of an elevated horizontal ladder (rung spacing:
5.2 +/− 0.3 cm) was tested in alternation with overground
walking. 10–15 steps per side were analyzed per rat.
Quantification of hit, slip or miss paw placement was
assessed from slow motion videos acquired at 100 Hz.
Principal Component Analysis
Behavioral data was analyzed by PC analysis [17]. Not
all the steps are depicted in the figures.
Step 1: Continuous locomotion is recorded using a
high-resolution kinematic system.
Step 2: Custom-written MATLAB scripts are applied to
reconstructed kinematic data in order to compute
basic parameters and highly elaborated variables that
provide a comprehensive quantification of gait
features. All variables computed are specified in
Additional file 1: Table S1. Approximately 10–15
steps were extracted per rat and experimental
condition.
Step 3: The matrix combining all values of variables
from all rats and steps was then subjected to a PC
analysis. For this purpose, we used the correlation
method, which adjusts the mean of the data to 0
and the SD to 1. This method allows the
comparison of variables with disparate values (large
versus small), and/or different variances. The result
of the PC analysis is a new set of synthetic
uncorrelated variables, i.e., the PCs, which each
explains the maximum possible amount of variance.
Step 4: The new coordinates of gait patterns along each
PC, termed PC scores, are extracted for each rat. PC
scores are used to represent gait patterns in the
“denoised” PC space to visualize differences between
mice and experimental conditions.
Step 5: PC scores are averaged for each experimental
condition and represented in histogram plots to
identify the type of information differentiated along
each PC axis.
Step 6: Each PC is a linear combination of the original
parameters with appropriate weights, which are
termed “factor loadings.” The values of factor
loadings range from −1 to 1, and correspond to
correlations between original parameters and a
given PC.
Step 7: Factor loadings with a high value (|factor
loading| > 0.5) are extracted, color-coded based on
their correlation value, and regrouped into
functional clusters based on the type of gait control
aspects they refer to. This process leads to an object-
ive extraction of the most relevant behavioral pa-
rameters to account for the effects of a specific
experimental condition (Additional file 2: Figure S6).
Step 8: To provide a more classical representation of
the observed effects, relevant parameters
representative of functional clusters are extracted
and represented in histogram plots.
Primate experiments
Surgery
Eight two-years-old (young group) and five six-years-old
(old group) common marmosets (Callithrix jacchus)
were unilaterally injected with 4 μL AAV-hα-syn in 2
points of the SNpc following electrophysiological record-
ings (AP: +4 and +3.3 mm, L: +3.7 and +3.5 mm,
D: +15 mm from interaural line). Recording system: 16
channel wireless system, Multichannel Systems, Reut-
lingen, BW, Germany). Animals were anaesthetized with
atropine SO4 at 0.04 mg/kg, i.m. prior to preparation for
surgery. At least 10 min later, the animals were anaesthe-
tized with ketamine HCl at 10 mg/kg, IM. Following
stereotaxic injections, viral expression was allowed for the
next eleven weeks.
Post-mortem processing
At the end of different experiments, animals were killed
by sodium pentobarbital overdose (150 mg/kg, i.v.), and
perfused transcardiacally with 0.9 % saline solution (con-
taining 1 % heparin) followed by 4 % PFA performed in
accordance with accepted European Veterinary Medical
Association guidelines. Brains were removed quickly
after death and post-fixed overnight in the same fixative,
then cryoprotected in PBS containing 20 % sucrose and
frozen by immersion in a cold isopentane bath (−45 °C),
before being stored at −80 °C until sectioning. Brains
were sectioned in a Leica CM3050S cryostat (Leica
Microsystems, Wetzlar, Germany) at −20 °C. Brains were
cut at 50 μm-thick sections and both striatal and SNpc
levels were collected.
Immunohistochemistry
Extent of lesion To assess the integrity of the nigros-
triatal pathway, tyrosine hydroxylase (TH) immunohisto-
chemistry was performed on striatal and SN free-floating
sections (Additional file 3: Table S2). On the rat experi-
ment, dopamine transporter (DAT) immunochemistry
on striatal sections was also done. Briefly, striatal sec-
tions from three representative levels (anterior, medial
and posterior) were incubated with a mouse monoclonal
antibody raised against human TH (Millipore, MAB318,
1/5 000) or rabbit polyclonal antibody raised against
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DAT ([18], 1/5 000) for 72 h at room temperature. The
staining was revealed by a specific peroxidase EnVision™
system (mouse or rabbit HRP EnVison™ kit DAB+
DAKO, K4007 or K4011) followed by DAB visualization.
Midbrain sections containing the SNpc were processed
for tyrosine hydroxylase. Serial Free-floating sections
were incubated in mouse monoclonal TH antibody
(Millipore, MAB318, 1/5 000) for one night at room
temperature and revealed by an anti-mouse peroxidase
EnVision™ system followed by DAB staining. SN free
floating sections are mounted on gelatinized slides,
counterstain with 0.1 % cresyl violet solution, dehydrated
and coversliped while striatal sections are mounted on
gelatinized slides and coversliped only.
Human α-syn expression Human α-syn expression
levels were revealed in the striatum (anterior, median
and posterior part) and in the SNpc by immunohisto-
chemistry (Additional file 3: Table S2). The selected
sections of the striatum, and serial free-floating sec-
tions of the SN were incubated with a mouse mono-
clonal antibody raised against human α-syn (clone
syn211 Thermo Scientific, MS1572, 1:1000) for one
night at room temperature and revealed by an anti-
mouse peroxidase EnVision™ system (DAKO, K4007)
followed by DAB incubation. Phosphorylated synu-
clein immunochemistry was investigated in the sub-
stantia nigra in mouse and marmoset experiments.
Briefly, serial sections of the SN were incubated for 3
nights at room temperature in a rabbit anti p-Syn
(Abcam AB51253 – 1/500) and revealed with the
rabbit HRP EnVision polymere system™ followed by
DAB as substrate. Free-floating sections were
mounted on gelatinized slides, dehydrated and cover-
slipped before further analysis.
Fluorescence co-localization Co-localization of Ubiqui-
tin and TH with α-syn was revealed by a triple fluores-
cence immunohistochemistry within the SNpc of sham
or AAV-hα-syn injected rat at 16 week post-surgery. All
sections were individually identified to perform staining
with all sections in the same conditions. After a blocking
step in 5 % fat milk, TH was first revealed with a sheep
anti TH (Abcam −1/1000) for one night followed by a
donkey anti-sheep Alexa 488 (1/500-1 h). The staining
was briefly observed under microscope before to con-
tinue with a simultaneous incubation of a mouse anti-α-
syn and rabbit anti-Ubiquitin both diluted at 1/1000 in
PBS. Then, the α-syn signal is revealed first by incubate
sections in a Alexa Cys5 goat anti mouse for 1 h at RT
and the double staining TH- α-syn was observed before
the last staining with an anti-rabbit HRP EnVision™ sys-
tem (DAKO, K4011) followed by an 549 Dylight anti
HRP diluted at 1/1000 for 1 h. Free-floating sections
were mounted on slides and coverslipped with fluoro-
mount™ aqueous mounting media (Sigma, F4680).
Image analysis
Grey level TH quantification in the striatum TH level
in the striatum is quantified by densitometry. Sections are
scanned in an Epson expression 10000XL high-resolution
scanner and images are used in ImageJ software to compare
the grey level in the delineated striatum for each animal.
Stereological assessment of TH positive cells in the
SN TH-positive SN cells were counted by stereology
blind with regard to the experimental condition using a
Leica DM6000B motorized microscope coupled with the
Mercator Pro software (ExploraNova, La Rochelle,
France).The SN was delineated for each section and
probes for stereological counting were applied to the
map obtained (sampling and size of probes, see Add-
itional file 4: Table S3). Each TH-positive cell with its
nucleus included in the probe or intersecting any of the
acceptance lines was counted. The optical fractionator
method was finally used to estimate the total number of
TH-positive cells in the SN of each animal.
α-syn and DAT surface quantification in the STR α-
syn expression and DAT staining were quantified in
the striatum on high-resolution images from Nano-
Zoomer 2.0 HT (BIC facility). Each NDPI image ob-
tained was used in Mercator Pro software (Explora
Nova, La Rochelle, France) to quantify the representa-
tive surface of α-syn or DAT staining within the stri-
atum. Briefly, striata were delineated and a color
threshold was applied for each image using the same
parameters allowing comparison between experimental
groups. The surface detected was then compared to
the whole striatum surface in order to obtain a per-
centage of stained structure.
α-syn and p-α-syn volume quantification in the SN
In order to quantify the expression of α-syn or p-α-syn
in the whole SN, a semi-stereological assessment was
used for each animal. As for the striatal α-syn quantifica-
tion, all slides with serial sections of the whole SNpc
were scanned in a NanoZoomer 2.0 HT (BIC facility).
First, NDPI images obtained were analyzed in Mercator
Pro software (Explora Nova, La Rochelle, France) to
quantify the representative surface of the staining in
each SN section using a color threshold. Then, surfaces
detected were reported to the sampling scheme
(Additional file 4: Table S3) to assess the representative
volume of α-syn or p-α-syn expression for each SN
using the Cavalieri method. Finally the percentage of SN
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volume stained for α-syn was used to compare the effect
of each treatment.
Results
α-syn overexpression induces a progressive degeneration
of the nigrostriatal pathway in rat
To determine the course of dopamine neuron degen-
eration, adult Sprague–Dawley rats received intrani-
gral stereotactic injection of AAV2/9 carrying human
p.A53T α-syn (AAV-hα-syn). We then assessed sev-
eral markers of the nigrostriatal pathway: tyrosine hy-
droxylase (TH) and dopamine transporter (DAT)
immunoreactivities in the striatum as well as the
number of TH-positive cells in the SNpc which all
correlated with the protein expression of hα-syn in
both striatum and SNpc at five time points (72 h, 1,
4, 8 and 16 weeks) (Fig. 1). Intranigral injection of
AAV-hα-syn resulted in a markedly significant reduc-
tion of dopaminergic fibers, evidenced by a reduction
of TH (Fig. 1a and f, Additional file 5: Figure S1a)
and DAT (Fig. 1b and f, Additional file 5: Figure S1b)
immunostaining, beginning at 1 week and reaching a
plateau at 4 weeks, associated with progressive dopa-
mine neuron death ranging from 50 % at 1 week to
approximately 80 % at 16 weeks after surgery (Fig. 1d
and f, Additional file 5: Figure S1c). A two-phase ex-
ponential decay equation models the time-course of
SNpc dopaminergic neuron loss (y =2230 +
3707.2728e-2.171x + 3417.877e-0.1069x, r2 = 0.66, Fig. 1f ).
These results indicate that nigral expression of hα-syn
induces progressive dopamine neuron degeneration in
rat, in agreement with previous findings [10, 19, 20].
We next attempted to examine the hα-syn expression
pattern in SNpc and striatum over time. Coinciding with
the onset of neurodegeneration (72 h after injection), we
observed a progressive increase in hα-syn around the injec-
tion site at 72 h that peaked at 8 weeks post-injection
(Fig. 1e and f, Additional file 5: Figure S1d). In the stri-
atum, hα-syn staining was detected weakly at 1 week
and reached its highest level at 4 weeks (Fig. 1c and
f, Additional file 5: Figure S1e) concomitantly with
the significant decrease in striatal dopamine markers
(Additional file 5: Figure S1a and b).
Anatomically, expression of hα-syn started in the SNpc
before being noticeable in the striatum (Additional file 6:
Figure S2a and b). A strong intraneuronal hα-syn staining
was observed at 72 h that then changed to a diffuse pat-
tern in later time points (Additional file 6: Figure S2a).
The striatum, on the other hand, showed long, wire-like,
staining from 1 week onwards, subsequently changing to a
more punctate form (Additional file 6: Figure S2b). In the
SNpc, hα-syn co-localized with ubiquitin in neuronal cells
at 8 weeks after injection (Additional file 7: Figure S3e-l),
in contrast to sham-operated rats (Additional file 7: Figure
S3a-d). Staining of hα-syn phosphorylated at S129 (p-α-
syn), a common marker for pathological α-syn in post-
mortem tissue [21], was observed specifically within SNpc
neurons in AAV-hα-syn-injected rats at 16 weeks
post-injection (Additional file 8: Figure S4b-e) but not in
sham-operated rats (Additional file 8: Figure S4a). P-α-syn
staining was mostly observed in perikarya of neuronal
cells as well as in dendritic terminals (Additional file 8:
Figure S4c-d). While hα-syn staining spread throughout
the whole mesencephalon at 16 weeks after surgery
(Fig. 1e), p-α-syn immunolabelling remained restricted to
SNpc neurons (Additional file 8: Figure S4). These results
indicate the presence of intracytoplasmic accumulation of
α-syn, positive either for ubiquitin or for p-α-syn, in AAV-
hα-syn-injected rats.
Because earlier work has shown differential rodent
strain neurodegeneration susceptibility to neurotoxin
[22], we then investigated whether two common la-
boratory rat strains, i.e., Sprague–Dawley and Wistar,
would display a different susceptibility to hα-syn over-
expression. Strikingly, Wistar rats were significantly
less susceptible to dopamine neuron degeneration
(45 % at 8 weeks) compared to Sprague–Dawley rats
(69 % at 8 weeks) (Additional file 9: Figure S5),
highlighting the importance of the genetic background
in the response to hα-syn overexpression.
α-syn overexpression induces a progressive motor
dysfunction in rats
The extent of lesion observed suggested that AAV-
hα-syn-injected rats might develop overt parkinson-
ism. While AAV-hα-syn-injected rats displayed a sig-
nificant decrease in spontaneous activity (Fig. 2a)
from 8 weeks post-surgery onwards, they showed a
significant decrease in the number of adjusting steps
as early as 4 weeks and thereafter (Fig. 2b).
We then conducted high-resolution kinematic analyses
to obtain quantified and detailed analyses of motor im-
pairments. We first evaluated the rats during self-
initiated overground locomotion. While sham rats fluidly
crossed the runway at a fast pace, AAV-hα-syn-injected
rats walked slower and exhibited a more variable and
shuffling gait pattern (Fig. 2c). To measure these deficits,
we computed 89 parameters providing quantitative mea-
surements of bilateral gait features (Additional file 1:
Table S1), and submitted all the parameters to a princi-
pal component (PC) analysis (n = 4 sham; n = 6 AAV-hα-
syn rats; 10–15 steps/rat/side). This method allows the
objective identification of the specific features that are
affected or not affected by injuries or experimental con-
ditions [23]. Representation of all data points in the de-
noised space created by PC1-3 (Fig. 2d) showed that the
gait patterns of healthy and AAV-hα-syn-injected rats
clustered in distinct spaces that minimally overlapped.
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Fig. 1 (See legend on next page.)
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Analysis of individual scores on PC1, which explained
18 % of the total variance, revealed a significant differ-
ence between healthy and AAV-hα-syn-injected rats
(p < 0.01; Fig. 2d). Thus, PC1 distinguished healthy from
AAV-hα-syn-injected rats. We next extracted the parame-
ters correlated with the AAV-hα-syn-specific PC1 (|factor
loading| > 0.5), and regrouped them in functional clusters
(Additional file 2: Figure S6). 38 % of all parameters ana-
lysed were altered in AAV-hα-syn-injected rats compared
to healthy animals. Analyses of these parameters revealed
that AAV-hα-syn-injected rats displayed altered gait tim-
ing, reduced control over limb endpoint trajectory and
velocity, increase medio-lateral instability and aberrant
inter-limb coordination (Fig. 2e).
We then tested rats during walking on a horizontal
ladder, requiring precision in foot placement. Whereas
sham rats progressed across the ladder with ease,
AAV-hα-syn-injected rats crossed the ladder at a re-
duced velocity, with occasional periods of freezing
(Additional file 10: Movie S1). They exhibited in-
accuracy in the positioning of the hind paws onto the
rungs compared to healthy rats (Fig. 2f ). This mis-
placement resulted in an increased percentage of slips
(healthy: 7.4 +/− 0.3 %; AAV-hα-syn rats: 13.1 +/−
4.7 %) and misses (healthy: 1.2 +/− 1 %; AAV-hα-syn:
7.6 +/− 4.8 %) in AAV-hα-syn-injected rats (Fig. 2g).
While individual rats displayed variable behaviours on
the ladder (Fig. 2g), this precision task uncovered
more pronounced motor deficits compared to basic
runway locomotion.
Taken together, these data indicate that the hα-syn-
induced nigrostriatal degeneration in the rat is accom-
panied by a progressive onset of motor dysfunctions
reminiscent of the impairments observed in PD patients.
Premature ageing mice did not present higher
susceptibility to α-syn overexpression
Because ageing remains the most compelling risk factor
for PD [2], we next investigated the relation between age-
ing and hα-syn-induced neurodegeneration using a panel
of mice strains. The C57Bl/6 J, the senescence-accelerated
mouse-prone 8 (SAMP8), the senescence-accelerated
mouse-resistant 1 (SAMR1), and their littermate controls
were used. The SAMP8 mice are naturally phenotypic
mutant born from a collection of inbred mice that exhibit
ageing alterations, such as age-dependent early onset of
senile amyloidosis, degenerative arthropathy, cataracts,
osteoporosis and osteoarthritis, reduced fecundity, early
loss of fecundity and a shorter life span (death typically
occurs at 8 months) [24]. The SAMR1 mice come from a
collection of three long-lived control strains [24]. SAMR1
and SAMP8 mice were raised on an AKR/J genetic
background.
The integrity of the nigrostriatal pathway was assessed
at 20 weeks after stereotactic surgery to cover the life
span of SAMP8 mice. While all strains displayed a sig-
nificant decrease in striatal TH immunoreactivity, only
C57Bl/6 J mice presented a significant decrease in the
number of TH-positive neurons in the SNpc (Fig. 3a).
SAMP8 and SAMR1 mice, on the AKR/J background,
are less susceptible to hα-syn-induced degeneration than
C57Bl/6 J mice. Whether this difference actually repre-
sents a delayed degeneration or an absence of degener-
ation remains to be fully established.
We then examined the occurrence and pattern of hα-syn
pathology at both striatal and nigral levels. All strains dem-
onstrated strong hα-syn staining at both levels (Fig. 3b). In
contrast to rats, p-α-syn staining was not restricted to
SNpc (Fig. 3c). Further examination revealed an intriguing
pattern for p-α-syn staining: C57Bl/6 J exhibited the stron-
gest pattern and SAMP8 the weakest (Fig. 3c). Interest-
ingly, p-α-syn levels and the number of TH-positive cells
in the SNpc were covariant: the strain with the highest
amount of p-α-syn (i.e., C57Bl/6 J) was also the one that
displayed the highest dopamine neuron death (Fig. 3d).
To establish that SAMP8 and SAMR1 mice were less
susceptible to PD-related neurodegeneration, animals
were treated with a subacute regimen of intoxication
with 1-methyl-1,2,3,6-tetrahydropyridine (MPTP), a pro-
parkinsonian mitochondrial neurotoxin that reproduces
several aspects of PD [25]. Only C57Bl/6 J mice dis-
played significant DA neurodegeneration 5 months fol-
lowing MPTP intoxication, a result reminiscent of our
observation in AAV-hα-syn injected animals (Additional
file 11: Figure S7). This result supports our hypothesis of
a lack of sensitivity of SAMP8 and SAMR1 mice, mostly
attributable to their AKR/J genetic background.
Taken together, our results in mice are three-fold.
First, we established that overexpression of hα-syn in-
duces neurodegeneration associated with accumulation
(See figure on previous page.)
Fig. 1 rAAV2/9 vector-mediated overexpression of hα-syn in rat SNpc induces progressive dopaminergic neurodegeneration related to hα-syn
expression dynamics. (a-e) Representative photomicrographs of dopaminergic markers and human α-syn immunostaining at striatal (a-c) and SNpc
(d,e) levels at several time points after injection. (a,d): tyrosine hydroxylase (TH); (b): dopamine transporter (DAT); (c,e): human α-syn. (f) Quantification
of the different markers over time. Briefly, stereological quantification of the number of TH-positive cells in the SNpc of rat are reported on the left axis,
all staining intensity have been normalized between min (0 %) and max (100 %) and reported on the right axis to allow comparison of the evolution.
Dot-lines represent actual values while plain curves are regression curves. Colors are the same as in the upper part of the panel: light blue: striatal TH,
purple: striatal DAT, yellow: striatal α-syn, blue: SNpc TH, red: SNpc α-syn. Scales applies to all pictures: 1 mm
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Fig. 2 (See legend on next page.)
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of α-syn and p-α-syn in mice. Second, phenotypic mu-
tants with either accelerated senescence or resistance to
senescence did not display differential susceptibility to
hα-syn overexpression and MPTP intoxication. Third, in
mice, p-α-syn levels correlated with nigrostriatal
degeneration.
Ageing does not enhance susceptibility to α-syn overex-
pression in marmoset monkeys
Non-human primate neuronal physiology is closer to
human than rodents. We thus took advantage of aged
and young adult marmoset monkeys to decipher
whether ageing might increase the susceptibility of dopa-
mine neurons to degenerate following AAV-hα-syn
injection.
The integrity of the nigrostriatal pathway was investi-
gated in young adult (1–2 years old, n = 8) and old mar-
mosets (>6 years old, n = 5). The life span is around
10 years, i.e., the old animals had exceeded their mid-life
expectancy. In humans, PD typically occurs around
60 years of age. Sham-operated old animals displayed a
significant reduction of TH immunoreactivity in the stri-
atum (40 % in the caudate nucleus and 43 % in the puta-
men) associated with a significant decrease of TH-positive
cells in the SNpc (29 %) compared to sham-operated
young animals (Fig. 4a). Animals were euthanized at
11 weeks post-surgery to avoid any losses due to death
from natural causes of some old animals. AAV-hα-syn
induced a degeneration of TH-positive neurons of the
same magnitude (13 % in young animals, 20 % in old
animals, p = 0.7182). At the striatal level, hα-syn over-
expression produced depletion in striatal TH-positive
fibers in both caudate nucleus (8 % for young and 11 %
for old animals – Fig. 4a) and putamen (23 % for young
animals and 15 % for old animals – Fig. 4a). These re-
sults indicate that hα-syn-induced degeneration of the
nigrostriatal pathway was not affected by the age of the
animals.
We then investigated the occurrence and pattern of
hα-syn pathology. The level of overexpression and
pattern of hα-syn staining were identical at both SNpc
and striatal levels in both groups (around 300 % -
Fig. 4b). Then, we examined p-α-syn immunostaining in
the SNpc (Fig. 4c). While both young and old animals
showed p-α-syn immunoreactivity only on the injected
side, old animals exhibited a significantly lower staining
than young animals (Fig. 4c). In contrast to mice (Fig. 3c)
but in agreement with our results in rat (Additional file
8: Figure S4), p-α-syn staining was mostly restricted to
SNpc and could be found in neuronal perikarya and
dendritic terminals (Fig. 4c). Nevertheless, p-α-syn and
the number of TH-positive neurons in the SNpc (Fig. 4d)
did not covary, unlike in mice (Fig. 3d). Both age groups
presented an identical level of nigrostriatal degeneration
regardless of the p-α-syn staining levels. This last obser-
vation raises questions as to the interpretation of p-α-
syn levels in different species.
Discussion
Here we report that AAV2/9-mediated p.A53T mutated
human α-syn overexpression induces robust nigrostriatal
neurodegeneration in mice, rats and monkeys, establish-
ing translational comparisons among species. In
addition, the comprehensive degeneration kinetics and
high-resolution kinematic characterizations in the rat
model uncovered clinically relevant relationships be-
tween the extent of the lesion and the behavioural PD-
like phenotype.
Previous studies have shown that overexpression of
human WT α-syn in rats induces around 80 % of dopa-
mine neuron loss after 16 weeks [19], a result compar-
able to the present p.A53T mutant α-syn overexpression
in the rat (80 % of DA cell loss after 16 weeks) and par-
alleled by only 30 % dopamine neuron loss in mice after
20 weeks and 20 % in aged marmoset monkeys after
11 weeks. Our results in the rat model are in agreement
with previous reports [10, 13] using the same expression
cassette, although the level and time frame of neurode-
generation varies depending on the titer and vector sero-
type used [10]. Patients harbouring p.A53T mutation do
(See figure on previous page.)
Fig. 2 Behavioral impairments associated with hα-syn overexpression in rats. a Spontaneous locomotor activity at baseline (Bsl) and at 4, 8, 12
and 16 weeks after surgery. b Stepping test at baseline and at 4,8,12 and 16 weeks after surgery. c Color-coded stick diagram decomposition of
hindlimb movement for a representative healthy and AAV-hα-syn rat during crossing of an elevated horizontal ladder with irregularly spaced
rungs (spacing 5.2 +/− 0.3 cm). The corresponding endpoint trajectory is shown below. The colour code indicated the instantaneous velocity of
the endpoint, while the arrows report the orientation and intensity of the foot push-off at swing onset. Light grey: stance; dark grey: hit; yellow:
slip; dark red: miss. d Pie charts summarize total percentage of hits, slips, and misses (total of 182 steps evaluated, n are indicated in the legend
boxes). Below percentage of hits, slips and misses are quantified as histogram plots. e The same representation is shown for a representative
healthy and Parkinsonian rat during overground locomotion. f Principal component (PC) analysis was applied on 89 gait parameters measured
during overground locomotion (10–15 gait cycles/hindlimb/rat, n = 4 healthy and n = 6 AAV-hα-syn rats). Each gait cycle is represented as a dots
in the new space created by PC1–3. Histogram plot depicts mean values of PC1 scores for each experimental group. g Histogram plots represent
mean values of parameters with high factor loading (|factor loading| > 0.5) on PC1, illustrating the most salient differences in motor control
between the two groups. Numbers refer to Additional file 1: Table S1. *p < 0.05; **p < 0.01; ***p < 0.001; $ p < 0.05 vs 4 weeks time point; error
bars, SEM; PC, Principal Component; a.u., arbitrary unit
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not present a classic parkinsonism but an early-onset,
fast-progressing disease associated with secondary symp-
toms [26]. Of interest, the dynamics of WT α-syn over-
expression [19] fit with our degeneration curve (Fig. 1f )
although one study reports a faster degeneration time
course for p.A53T mutant α-syn overexpression [20]. In
mice, one study did not show any significant differences
between WT and p.A53T mutated α-syn overexpression
[9]. Such differences might be attributable to the use of
different expression cassettes, as it appears in other re-
ports that dose of vector could be more important than
the α-syn mutation [9, 22]. The present data suggest that
this mutation might not have the same functional conse-
quences in rodents and marmoset monkeys as in
humans. The reason for the discrepancy between differ-
ent clinical symptoms and identical rates of degeneration
in preclinical models remains to be established. The
presence of an alanine residue at position 53 is not fully
conserved during evolution. Several species, including
rodents and marmoset monkeys, exhibit a threonine in-
stead of an alanine residue at position 53 in their en-
dogenous α-syn [27, 28]. Investigation in a mammalian
model that does not have the A53T substitution (such as
macaques) might resolve this apparent discrepancy.
Fig. 3 Human α-syn overexpression induces dopaminergic neurodegeneration associated with α-syn pathology in mice. a Stereological cell counts of
SNpc TH-positive neurons (left two panels, n = 4 animals for each genotype) and mean grey values of striatal TH immunoreactivity (right two panels) at
20 weeks after surgery compared to non-injected side (white bars). Top panels display representative TH immunostaining at SNpc (left) and striatum
(right) levels in the three mouse strains. b Volume quantification of the hα-syn immunostaining at the SNpc level (left two panels) and surface
quantification of the hα-syn immunostaining at the striatal level (right two panels) at 20 weeks after surgery. Top panels display representative hα-syn
immunostaining at SNpc (left) and striatum (right) levels in the mouse strains used. c Volume quantification of the p-α-syn immunostaining at the SNpc
level at 20 weeks after surgery. Left panels display representative p-α-syn immunostaining at SNpc at macroscopic (left) and microscopic (right) levels in
all mouse strains. d Covariance analysis of each parameter measured in all mouse strains. Data regarding TH pathway are expressed as a percentage of
loss of TH fibers or cell bodies. Syn data are expressed as a percentage of immunopositive surface of the structure of interest. STR: striatum; * p < 0.05
vs non injected side of C57Bl/6 J mice; # p < 0.05 vs non injected side of the AKR/J background mice concerned. Scales: 1.5 mm for STR, 0.5 mm for
SNpc and 20 μm for high magnification pictures of the C panel. hα-syn: human α-syn; p-α-syn: S129 phosphorylated α-syn
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The behavioural phenotype of AAV-hα-syn-injected rats
shares many features with the human disease. In the open
field and locomotor tasks, AAV-hα-syn-injected rats dis-
played both akinesia and bradykinesia. L-3,4-dihydroxy-
phenylalanine treatment effectively alleviates these
symptoms [15]. Here, we quantified these deficits using
objective and quantitative analyses. We found that a de-
crease in velocity (gait hypokinesia) and abnormal gait, as
evidenced by impaired inter-limb coordination and in-
creased double stance were the main features altered in
response to α-syn over-expression. These features
constitute the hallmarks of shuffling gait in PD patients
[26]. The longitudinal follow-up of basic motor function
allowed us to establish that motor dysfunction appears
from 4 weeks onwards, when 60 % of dopamine neurons
and 80 % of striatal dopaminergic fibers have been lost.
These results are in perfect coherence with the known or
hypothesized relationship between nigrostriatal lesions
and symptoms in MPTP-treated macaques [29] and PD
humans, respectively [30]. Applying the regression defined
for the AAV-hα-syn-injected rats to the AAV-hα-syn-
injected mice and monkeys, for which we have a single
Fig. 4 Human α-syn overexpression induces dopaminergic neurodegeneration associated with α-syn pathology in young and old marmoset monkeys.
a Stereological cell counts of SNpc TH-positive neurons (left panel, n = 8 for young animals and n = 5 for old animals) and mean grey values of striatal
TH-positive fibers (right panel) at 11 weeks after surgery. Colors: blue: injected side of young animals; red: injected side of old animals; white and light
grey: non-injected side of young and old animals, respectively. Top panels display representative TH immunostaining at SNpc (left) and striatum (right)
levels. b Volume quantification of the hα-syn immunostaining at the SNpc level (left panel) and surface quantification of the hα-syn immunostaining at
the striatal level (right panel) at 11 weeks after surgery. Top panels display representative hα-syn immunostaining at SNpc (left) and striatum (right)
levels. c Volume quantification of the p-α-syn immunostaining at the SNpc level at 11 weeks after surgery. Left panels display representative human
p-α-syn immunostaining at SNpc at macroscopic (left) and microscopic (right) levels. d Covariance analysis of each parameter measured in young and
old marmosets. Data regarding TH pathway represent a loss of TH fibers or cell bodies. STR: striatum; * p < 0.05 vs non injected side of young animals;
# p < 0.05 vs non injected side of old animals; & p < 0.05 vs injected side of young animals. Scales: 1.5 mm for STR, 0.5 mm for SNpc, 250 μm and
20 μm for high magnification pictures of the (c) panel. hα-syn: human α-syn; p-α-syn: S129 phosphorylated α-syn
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time point, led us to predict that symptoms would be de-
tected, post-surgery, at 133 weeks in mice, 244 weeks for
young marmosets and 142 weeks for old marmosets.
While such duration would exceed the mouse life span,
rendering the model inadequate for behavioural studies,
the durations are indeed compatible with marmoset life
span. These extrapolations suggest that age may impact
upon the development of symptoms, which remain to be
confirmed. However, this long-term window excludes the
involvement of marmoset monkeys in behavioural studies,
restricting the use of this species for studies relying on
post-mortem endpoints. Previous work suggested that,
after the first occurrence of clinical signs, the evolution of
the disease slows down [30]. Contrary to the MPTP-
treated monkey model, in which degeneration of
dopamine neurons fits with a linear regression [29, 30],
AAV-hα-syn injection in the rat followed an exponen-
tial regression equation characteristic of a fast onset of
neurodegeneration followed by a slow evolution, a fea-
ture to bear in mind both for the study of the pro-
dromal phase and for the validation of therapeutic
approaches.
Several studies have reported the existence of p-α-syn
in brains from PD patients [21]. α-syn could indeed be
phosphorylated at S129 in preclinical models of PD [19,
31, 32]. However, it remains unclear from in vitro and
in vivo data whether phosphorylation of α-syn impacts
upon its fibrillation process [33]. We here show that
mice exhibiting the highest p-α-syn levels display the
highest level of degeneration. However, the marmoset
monkey data contradict this hypothesis as no correlation
between the p-α-syn levels and DA degeneration was
found in this species. Several other reports have already
questioned the relevance of p-α-syn to the neurodegen-
erative process and as a therapeutic target [34]. Our data
suggest that p-α-syn might have different impact de-
pending upon the species, calling for caution in inter-
preting data obtained in rodents compared to primates.
It may be noted that p-α-syn is found in healthy aged
human brains [35].
A key objective of the present study was to address
the role of ageing in the susceptibility of dopamine neu-
rons to degeneration in mice and marmoset monkeys. In
mice, aged animals are more prone to MPTP-induced
striatal dopamine loss [36]. The absence of neurodegen-
eration after hα-syn overexpression or MPTP adminis-
tration observed in SAMP8 and SAMR1 mice might be
due to their AKR/J background, which is known to be
less sensitive to MPTP than C57Bl/6 J [22]. Whether this
is indeed a lack of sensitivity or the consequence of an
unknown neuroprotective factor remains to be estab-
lished. Similar to the differential rat strain susceptibility,
these results call for caution regarding genetic back-
ground when using genetically engineered or mutant
mice for studying PD pathogenesis. A previous study
using MPTP in marmoset monkeys reported that aged
marmosets (8–10 years-old) were no more susceptible to
MPTP intoxication than younger animals [37], a finding
consistent with our results using α-syn-induced neuro-
degeneration. In rhesus monkeys, aged animals (20–23
years-old) required a third as much MPTP to induce the
same behavioural phenotype as in young animals [38],
suggesting an age-dependent susceptibility. The differen-
tial MPTP susceptibility between these two species
might be due to the presence of neuromelanin, a pigment
that accumulates over time in the SNpc through oxidation
of dopamine to aminochrome and polymerization, in ma-
caques but not in marmosets [39]. Melanized neurons are
more susceptible than non-melanized neurons both in PD
patients [40] and MPTP-treated primates [41]. Further
studies are needed to unravel whether the presence of
neuromelanin in aged macaques, and to a lesser extent in
young macaques, might impact the degeneration course
following hα-syn overexpression. The specificity of
primate brain for the accumulation of neuromelanin
strengthens the special relevance of preclinical studies in
primates for PD. Nevertheless, ageing here appears as a
modest independent factor that only decreases the gap to
a putative threshold for the appearance of PD symptoms
in marmoset monkey. Our results thus strengthen the
multiple-hit hypothesis [4, 42]. We propose that a com-
bination of deleterious events accelerate the ageing-
related decline in dopamine neuron function, rather than
the stochastic acceleration hypothesis in which ageing dir-
ectly sensitizes the dopamine system [3].
Conclusions
Ageing might only be a contributing factor to the extent
of hα-syn-induced degeneration, suggesting that mature
adult animals might be enough for testing disease-
modifying therapies. Since PD patients would only bene-
fit from such therapy after symptom onset, i.e., when
they already have a loss of 70-80 % of striatal dopamin-
ergic terminals and 50-60 % of dopamine neurons, the
present study defines the most suitable time points for
therapeutic intervention in those three models. Consid-
ering the identified dynamics (Fig. 1), we propose that
starting administration from 3–4 weeks after surgery in
the AAV-hα-syn rat model would be most clinically-
relevant, offering translatable behavioural and post-
mortem endpoints while the mouse and marmoset
models should be used for post-mortem endpoints only.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
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Additional files.
Additional file 1: Table S1. Computed kinematic and kinematic
variables.
Additional file 2: Figure S6. Extraction of gait parameters affected by
hα-syn overexpression in rats. PC analysis was applied on all gait
parameters measured during overground locomotion, as reported in
Fig. 2. Parameters correlating with PC1 (|loading factor| > 0.5) and thus
specifically altered by hα-syn overexpression were regrouped into
functional clusters, which we named for clarity. The numbers refer to
Table S1. Some of the parameters with high factor loadings are reported
in the histogram plots of Fig. 2.
Additional file 3: Table S2. List of antibodies used in the study
Additional file 4: Table S3. Sampling and size of probes used in the
study.
Additional file 5: Figure S1. rAAV2/9 vector-mediated overexpression
of hα-syn in rat SNpc induces progressive dopaminergic neurodegeneration
related to hα-syn expression dynamics. (a-e) Histogram plots represent
mean values of DA related (a-c) or hα-syn (d,e) related markers. *: p < 0.05 vs
sham animals, $ : p < 0.05 vs 72 h, # : p < 0.05 vs 1 week. Errors bars are SEM.
hα-syn: human α-syn.
Additional file 6: Figure S2. Striatal and SNpc hα-syn expression. Delay
between SNpc (a) and striatal (b) hα-syn expression. Hα-syn pattern in
the SNpc starting from a strong cellular staining (a – early time points) to
a more diffuse one (a – late timepoints). In the striatum, morphological
change of hα-syn staining from a long-wire staining (b - early timepoints)
to a more punctiform one (b – late time points). Scale bars: (a) 50 μm, (b)
20 μm. hα-syn: human α-syn.
Additional file 7: Figure S3. Presence of ubiquitin-hα-syn colocalization
in SNpc remaining neurons. (a,e,i) TH staining, (b,f,j) ubiquitin, (c,g,k) hα-syn
(d,h,l) merge. (a-h) ×10 magnification, (i-l) ×40 magnification. hα-syn: human
α-syn
Additional file 8: Figure S4. p-α-syn staining in the SNpc. (a-d)
Representative photomicrographs of p-α-syn staining in the SNpc of
sham (a) or injected (b-d) animals. In contrast to hα-syn staining, p-α-syn
is highly localized in neuronal perikarya (c) and neurites (d) at 16 weeks
after surgery. (e) Quantification of the SNpc volume positive for p-α-syn
staining. Scale bar: (a,b) 1 mm, (c) 20 μm. hα-syn: human α-syn, pα-syn:
S129 phosphorylated α-syn.
Additional file 9: Figure S5. Wistar rats are significantly less sensitive to
hα-syn overexpression than Sprague Dawley rats. Histogram plots
represent number of TH-positive cells in the SNpc at 8 weeks after
surgery for sham (white bars) and AAV-hα-syn injected rats (black bars).
***: p < 0.01 vs control side, #: p < 0.05. Error bars: SEM.
Additional file 10: Movie 1. Locomotion across an horizontal ladder in
sham and AAV-hα-syn-injected rats. This movie shows a representative
kinematic recording of quadrupedal locomotion along the equally spaced
rungs of an horizontal ladder in a sham operated and an
AAV-hα-syn-injected rat.
Additional file 11: Figure S7. SAMP8 and SAMR1 mice do not
present nigrostriatal degeneration after MPTP intoxication while C57Bl/6 J
does. Histogram plots represent the number of remaining TH-positive
cells in the SNpc 21 days after the last injection of MPTP. *: p < 0.05 vs
non injected animals.
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